The Rs 110 crore drug delivery company, Mumbai-based Themis Laboratories is escalating its international presence in US, Europe Russia and South Africa. The company has already started the dossier filing procedure in all these counties and is targeting that by end 2010, it will have an extensive presence in all these countries.
Naresh Shah, President - Marketing, Global Business, said, "We are in the process of filing dossiers for the US, Europe, Russia and South Africa markets. In each country, we will be filing seven to eight dossiers and for South African market we have already filed seven dossiers."
Recently, the company has commissioned its new state of the art manufacturing facility in Ambernath, near Mumbai. The new manufacturing facility is highly equipped with modern technology for manufacturing pellets, granules, capsules and tablets. Shortly, the company will be applying for the regulatory approvals like US FDA, UK MHRA, Australia-TGA, Brazil-ANVISA, EMEA. "From our new manufacturing facility we are targeting better business opportunity from regulated markets. We are targeting that by end of next financial fiscal, we will have regulatory approvals in our hands,” averred Shah.
The company has therapeutic presence in gastrointestinal, cardiovascular, Central Nervous System (CNS), hypoglycaemias, anti-infectives and pain management segments. Currently, its product basket holds over 100 products. Themis Laboratories is also focussing on nanotechnology, biopharmaceuticals etc.
"From the beginning our niche therapeutic focus remains on New Drug Delivery System (NDDS) on oral manufacturing activity but now we are in the process of expanding our capabilities further to areas like nanotechnology, biopharmaceuticals transformational (research). Overall, we are getting higher sales from lifestyle diseases," commented Ankur Shah, Executive Director, Themis Laboratories.
Themis Laboratories has occupied 80,000 sq ft land in Rabale, Navi Mumbai for setting up a new R&D centre. The company has planned to invest Rs 30 crore and is expecting that full fledged commercial activity will commence from mid 2010. "Our current R&D centre is on lease and we are having strong product pipeline for all existing therapeutics. We have 25-30 products in the pipeline and currently all are in different stages of completion. We expect that market availability of all these products will be in another 15-18 months. Once our new R&D centre is ready we will be shifting our entire R&D set up to the new centre. Funds for building the new R&D centre have been raised through internal accruals and also from private equity," adds Ankur Shah.
The company has 60 scientists in its current R&D centre and is planning to add 40 scientists for new centre. Overall, it has a manpower strength of 400 people and will further add 100 people. It has registered a Compound Annual Growth Rate (CAGR) of 50 percent. With the current turnover of Rs 110 crore, it is targeting that by the fiscal end of 2015 it will have a turnover of Rs 500 crore.
Explaining about their inorganic growth strategies, Ankur Shah said, "We are foraying into regulated markets and seeing better business opportunities. We are also looking out for marketing tie ups from both domestic as well as from international market."